NCT06716281View on ClinicalTrials.gov

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

PHASE3RecruitingINTERVENTIONAL
Enrollment

398

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

Human umbilical cord mesenchymal stem cells

a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL

BIOLOGICAL

Placebo

Sodium Chloride Injection

Trial Locations (1)

Unknown

RECRUITING

The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai IxCell Biotechnology Co., LTD

OTHER